Interstitial cystitis (IC) is a chronic bladder inflammatory disease that is characterized by symptoms such as urinary urgency, frequency, nocturia, and suprapubic and pelvic pain and that mainly affect women. Although the exact etiology and pathogenesis of IC is unknown, one etiologic theory that has been dominantly reported in relation to the bladder immune is that of a localized allergic reaction \[[@B1],[@B2]\]. As reviewed by Theoharides et al. \[[@B1]\] and Rudick et al. \[[@B2]\], both clinical and experimental evidence show that IC is closely associated with an accumulation of mast cells and their activation, especially in the detrusor, lamina propria, and submucosa. This theory was first introduced after the beneficial therapeutic use of antihistamines in IC patients \[[@B3]\]. Recently, detrusor mast cell migration and activation and urinary histamine metabolites have been detected in IC patients and in experimentally induced animal models \[[@B4]-[@B6]\]. Concerning these points, both the bladder pathophysiology and pelvic pain are dependent on mast cells. However, whereas pharmacological modulators of histamine receptors can be evaluated as therapeutic agents to improve chronic pelvic pain, they do not act on the pathophysiology, which is mediated by tumor necrosis factor (TNF)-α. These results indicate different causative factors for bladder pain and the pathophysiological inflammation \[[@B2]\].

Mast cells are well known to be involved in both acute and chronic forms of allergic, type I hypersensitivity reactions. Mast cells are highly granulated cells that populate tissues including muscles and mucosal surfaces. Mast cells matured in these tissues are partially or completely degranulated by a wide range of immunologic and nonimmunologic stimuli. After activation, a characteristic pattern of mast cell mediators is released during degranulation. These include preformed granule-associated inflammatory mediators (e.g., histamine, heparin, neutral proteases, proteoglycans, glycoprotein-like YKL-40, chemotactic substances, and cytokines such as TNF-α), newly synthesized mediators (e.g., prostaglandin D2 \[PGD2\], leukotriene B4 and C4, interleukin-6 \[IL-6\], platelet-activating factor, and nitric oxide), and potent vasodilatory mediators (e.g., vasoactive intestinal peptide) \[[@B1],[@B7],[@B8]\]. These mast cell-released mediators are implicated in causing IC bladder pathophysiology (e.g., apoptotic lesions in the urothelium and urothelial or mucosal barrier dysfunction) and bladder-associated pelvic pain. Furthermore, the serum and urine levels of a new biomarker YKL-40, which is expressed in bladder mast cells, can be evaluated as an inflammatory mediator of bladder fibrogenesis in IC patients \[[@B8]\]. Also, IL-6 released from mature mast cells is elevated in the urine of IC patients and is highly increased in such patients with severe inflammation \[[@B9]\]. Thus, direct control via mast cell death or physiological blockade of bladder mast cell function is a reasonable strategy for reducing the severity of IC.

Mast cell survival and activation, which are mediated mainly by phosphorylation signals, can be negatively regulated by engaging the inhibitory receptors (IRs) containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Upon activation, the tyrosine residues of the ITIM sequences of the IRs are phosphorylated by the Src family of protein kinases \[[@B10]\]. The tyrosine phosphorylation typically induces recruitment of phosphatases, such as SHP-1 and SHP-2, and SH2-containing inositol phosphatases to the plasma membrane, which are then activated. Mast cell degranulation, for example as induced via FcεRI, is inhibited by this phosphatase-induced dephosphorylation mechanism \[[@B11]\].

A classic form of several IRs on human mast cells is FcγRIIB, which can down-regulate mast cell activation when co-ligated with high-affinity IgE receptor (FcεRI) \[[@B7]\]. In addition to the classic FcγRIIB form, mast cells also express one or more ITIM sequence-containing IRs, such as sialic acid-binding immunoglobulin-like lectins (Siglecs), on the cell surface to regulate their inflammatory or allergic activation. In this short review, we introduce the potential application of Siglec antibodies to the mast cells to activate Siglec IRs in the inflammatory urinary bladder disease IC.

Siglecs are members of an immunoglobulin superfamily. They are type 1 transmembrane proteins containing a unique N-terminal \'V-set\' Ig domain that can bind sialic acid and variable numbers of extracellular \'C2-set\' Ig domains. Most Siglecs (CD22 \[Siglec-2\]- and CD33 \[Siglec-3\]-related forms) also have a conserved cytosolic domain containing single or repeated ITIMs or ITIM-like motif sequences that are actively phosphorylated and that display inhibitory signaling functions. In particular, the genes for the CD33-related Siglecs (Siglec-3, -5, -6, -7, -8, -9, and -10) are located on chromosome 19 and have one or two ITIM sequences \[[@B12]-[@B14]\]. These Siglecs have been implicated mainly in the functional regulation of leukocytes via triggering signals via their ITIMs. Indeed, an important role of the CD33-related Siglecs is to regulate cell expansion by inhibiting or inducing apoptosis in leukocytes, but there are no reports of such activity in mast cells.

In human mast cells, CD22 (Siglec-2), CD33 (Siglec-3), and Siglecs-5 though -10 \[[@B15],[@B16]\] are expressed at differential levels. In particular, the expression of the eosinophil-selective Siglec-8 is also found weakly on basophils but prominently on mast cells. In functional experiments, activation of Siglec-8 by a specific monoclonal antibody (mAb) induced eosinophil apoptosis via caspase- and reactive oxygen species (ROS)-dependent processes. In contrast, these antibodies failed to induce mast cell apoptosis but did inhibit by at least 50% histamine and PGD2 release triggered via FcεRI. Additionally, in studies with human mast cells and Siglec-8 transfected RBL cells, activation (crosslinking) of Siglec-8 with mAb inhibited IgE receptor-mediated beta hexosaminidase release and calcium influx, the latter of which is required for mast cells degranulation \[[@B17],[@B18]\]. Indeed, normal human mast cells like LAD2 cells dominantly express Siglec-6 and -7 and moderately express Siglec-3 and -5, although expression is variable according to the culture stages of the mast cells. In our *in vitro* preliminary study in LAD2 cells, crosslinking of each of these Siglecs before FcεRI-stimulation, or simultaneously co-crosslinking a given Siglec mAb and IgE, partially inhibited histamine secretion \[unpublished data\]. As suggested also by Bochner \[[@B19]\], activation of Siglecs other than Siglec-8 would be expected to inhibit ITAM (immunoreceptor tyrosine-based activating motif)-dependent secretory responses in mast cells. Therefore, activating mast cell Siglecs with specific mAbs, or glycan liagnds specific for a particular Siglec) could be used to down-regulate mast cell function.

Increased numbers and activation of urinary bladder mast cells are major contributors to the pathophysiology of both ulcer and non-ulcer IC and in toxin- or chemical-induced animal models of IC. Although there are no reports targeting Siglecs or other mast cell IRs as a treatment for IC, the identification of these IRs on bladder infiltrated-mast cells would further our understanding of the mast cell phenotype in this disease, and may provide enthusiasm for the utilization of Siglec-specific mAbs or their glycan ligands to deliver inhibitory signals *in vivo* to mast cells as a potential treatment to reduce IC-induced bladder mast cell expansion and activation.
